Dual-pharmacology muscarinic antagonist and β 2 agonist molecules for the treatment of chronic obstructive pulmonary disease

Future Medicinal Chemistry

Volumn 3, Issue 13, 2011, Pages 1585-1605

  Hughes, Adam D ^a   Jones, Lyn H ^b  

^a THERAVANCE INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; ACLIDINIUM PLUS FORMOTEROL; ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BREEZHALER; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CARMOTEROL PLUS TIOTROPIUM; CORTICOSTEROID; DEXPIRRONIUM; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCOPYRRONIUM BROMIDE; GSK 573719; GSK 961081; INDACATEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MUSCARINIC RECEPTOR BLOCKING AGENT; NAPADISYLATE SALT; OLODATEROL; ONBREZ; QVA 149; SALMETEROL; TD 5959; THRX 198321; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VILANTEROL;

BLOOD BRAIN BARRIER; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; OXYGEN THERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TASTE; TREMOR; XEROSTOMIA;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 80053196166     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.106     Document Type: Review

References (64)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD).Lancet 364(9434), 613-620 (2004). (Pubitemid 39094180)
2. Chapman KR, Mannino DM, Soriano JB et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 27(1), 188-207 (2006). (Pubitemid 43092683)
3. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should).Proc. Am. Thorac. Soc. 4(7), 522-525 (2007). (Pubitemid 47547846)
4. Van Diemen CC, Boezen HM. Genetic epidemiology of reduced lung function. Lung Biol. Health Dis. 218, 17-31 (2007).
5. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 128(4), 2099-2107 (2005). (Pubitemid 41507547)
6. van Weel C, Schellevis FG. Comorbidity and guidelines: conflicting interests. Lancet 367(9510), 550-551 (2006). (Pubitemid 43247552)
7. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 350(10), 1005-1012 (2004). (Pubitemid 38269277)
8. Calverley PMA, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775-789 (2007). (Pubitemid 46294610)
9. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361(9356), 449-456 (2003). (Pubitemid 36173708)
10. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 22(6), 912-919 (2003). (Pubitemid 37540641)
11. COMBIVENT inhalation aerosol study group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85 day multicenter trial. Chest 105(5), 1411-1419 (1994).
12. COMBIVENT inhalation solution study group. Routine nebu0lized ipratropium and albuterol together are better than either alone in COPD. Chest 112(6), 1514-1521 (1997).
13. Oates JA, Wood AJJ, Gross NJ. Ipratropium bromide. N. Engl. J. Med. 319(8), 486-494 (1988).
14. Ahrens RC, Smith GD. Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. Pharmacotherapy 4(3), 105-121 (1984). (Pubitemid 14075131)
15. Reynolds NA, Perry CM, Keating GM. Budesonide/formoterol: in chronic obstructive pulmonary disease. Drugs 64(4), 431-441 (2004). (Pubitemid 38333656)
16. Johnson M. Salmeterol. Med. Res. Rev. 15(3), 225-257 (1995).
17. Spencer CM, Jarvis B. Salmeterol/ fluticasone propionate combination. Drugs 57(6), 933-940 (1999).
18. Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled salmeterol/ fluticasone propionate: a review of its use in asthma. Drugs 65(12), 1715-1734 (2005). (Pubitemid 41149029)
19. Keating GM, McCormack PL. Salmeterol/ fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs 67(16), 2383-2405 (2007). (Pubitemid 350080283)
20. 2-adrenoceptor agonist. Drugs Future 30(12), 1219-1224 (2005).
21. 2 adrenergic receptor agonists incorporating metabolicinactivation: an antedrug approach. J. Med. Chem. 53(11), 4522-4530 (2010).
22. 2-adrenoceptor agonist with a 24h bronchodilatory efficacy. Bioorg. Med. Chem. Lett. 20(4), 1410-1414 (2010).
23. Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today 38(9), 585-600 (2002). (Pubitemid 35190691)
24. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol. 155(3), 291-299 (2008).
25. Toy EL, Beaulieu NU, McHale JM et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir. Med. 105(3), 435-441 (2011).
26. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2(4), 297-304 (2005). (Pubitemid 41566939)
27. 2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 23(4), 257-267 (2010).
28. Vincken W. An update on bronchodilator treatment of chronic obstructive pulmonary disease (COPD).Ann. Respir. Med. 1(2), (2010).
29. Cazzola M, Centanni S, Santus P et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir. Med. 98(12), 1214-1221 (2004). (Pubitemid 39497224)
30. van Noord JA, Aumann JL, Janssens E et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir. Med. 104(7), 995-1004 (2010).
31. Cazzola M, Di Marco F, Santus P et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 17(1), 35-39 (2004). (Pubitemid 37468407)
32. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 26(2), 214-222 (2005). (Pubitemid 41079064)
33. Lee C, Corren J. Budesonide/formoterol in the treatment of asthma. Expert. Rev. Respir. Med. 2(5), 551-564 (2008).
34. van Noord JA, Buhl R, Laforce C et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65(12), 1086-1091 (2010).
35. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J. 34(3), 757-769 (2009).
36. Antoniu SA, Carone M, Sampablo I. Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier, the better? Expert Opin. Pharmacother. 11(6), 1039-1042 (2010).
37. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr. Opin. Pulm. Med. 16(2), 97-105 (2010).
38. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48(21), 6523-6543 (2005). (Pubitemid 41504710)
39. Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10(3), 197-208 (2011).
40. Mammen M, Choi SK, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37(20), 2755-2794 (1998).
41. 3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin. Invest. Drugs 13(11), 1493-1500 (2004). (Pubitemid 39530201)
42. Hughes AD, Chin KH, Hegde SS et al. Multivalent muscarinic antagonists for the treatment of overactive bladder (OAB).Presented at: 234th ACS National Meeting. Boston, MA, USA, 19-23 August 2007.
43. Ritchie TJ, Luscombe CN, Macdonald SJF. Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet? J. Chem. Inf. Model. 49(4), 1025-1032 (2009).
44. Sentellas S, Ramos I, Alberti J et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur. J. Pharm. Sci. 39(5), 283-290 (2010).
45. Leusch A, Eichhorn B, Muller G, Rominger KL. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Biopharm. Drug Dispos. 22(5), 199-212 (2001).
46. 2 adrenoceptor agonist (MABA) dual pharmacology molecules. Bioorg. Med. Chem. Lett. 21(5), 1354-1358 (2011).
47. 2- adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol. Pharmacol. 79(3), 389-399 (2011).
48. 2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation. Respir. Med. 97(Suppl. A), S23-S33 (2003). (Pubitemid 36124428)
49. McNamara A, Pulido-Rios MT, Hegde SS, Martin WJ. Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents. J. Pharmacol. Toxicol. Methods 63(1), 89-95 (2010).
50. Jacobsen JR, Aiyar J, Hegde S, Hughes AD, Mammen M. Dual-pharmacology bronchodilators for the treatment of COPD. Prog. Respir. Res. 39, 39-45 (2010).
51. 2-adrenergic agonist with potent and sustained in vivo bronchodilator activity in guinea pigs. Am. J. Respir. Crit. Care Med. 179(1), A6195 (2009).
52. 3 receptor antagonists with (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2- hydroxyphenylacetamide structures. Part 2. Bioorg. Med. Chem. Lett. 13(13), 2167-2172 (2003). (Pubitemid 36694298)
53. 2-adrenoceptor agonists with a long duration of action. Bioorg. Med. Chem. Lett. 19(17), 5237-5240 (2009).
54. 3 antagonists for the treatment of COPD. Bioorg. Med. Chem. Lett. 21(9), 2759-2763 (2011).
55. Michel MC, Hegde SS. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites? Naunyn-Schmiedeberg's Arch.Pharmacol. 374(2), 79-85 (2006). (Pubitemid 44657614)
56. 2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J. Med. Chem. 53(18), 6640-6652 (2010).
57. 3 antagonists for the treatment of COPD. MedChemComm 2(9), 870-876 (2011).
58. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care 50(9), 1209-1227 (2005). (Pubitemid 46187575)
59. Murnane D, Martin GP, Marriott C. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals. J. Pharm. Sci. 98(2), 503-515 (2009).
60. Disse B, Speck GA, Rominger KL, Witek TJ, Jr., Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 64(6/7), 457-464 (1999). (Pubitemid 29066693)
61. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug. Discov. 5(9), 730-739 (2006). (Pubitemid 44323700)
62. 2- adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. Br. J. Pharmacol. 158(1), 287-299 (2009).
63. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br. J. Pharmacol. 147(Suppl. 2), S80-S87 (2006). (Pubitemid 43237576)
64. Zhang MQ, Wilkinson B. Drug discovery beyond thérule-of-five'. Curr. Opin. Biotech. 18(6), 478-488 (2007).